SOURCE: AtheroGenics

February 06, 2007 11:07 ET

AtheroGenics Announces Promotion of Charles A. Deignan to Vice President of Finance and Administration

ATLANTA, GA -- (MARKET WIRE) -- February 6, 2007 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that Charles A. Deignan has been promoted to Vice President of Finance and Administration and Principal Accounting Officer. Previously Senior Director of Finance and Administration, Deignan will continue to report to Mark P. Colonnese, Executive Vice President of Commercial Operations and Chief Financial Officer.

In his new position, Mr. Deignan will assume the additional responsibility of Principal Accounting Officer. He will also continue to oversee the Company's accounting, treasury, financial planning, human resources and information systems functions.

"Charlie has made many significant contributions to our finance and administration department since joining the company seven years ago," stated Mr. Colonnese. "We are very pleased to announce his promotion to vice president, where his expertise and leadership will be instrumental as we guide our company into its next phase of growth."

Mr. Deignan, who joined AtheroGenics as Director of Finance in 1999, was promoted to Senior Director of Finance and Administration in 2002. Prior to joining AtheroGenics, Mr. Deignan held several financial management positions at AAIPharma, Inc. from 1994 to 1999, most recently as Division Controller. From 1988 to 1994, Mr. Deignan was employed by Schering-Plough Corporation, most recently as Financial Manager. Mr. Deignan received a B.S. in Business Administration from Boston University and is a Certified Managerial Accountant.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis, in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit

Contact Information

  • AtheroGenics, Inc.
    Donna L. Glasky
    Corporate Communications
    Email Contact

    Media Inquiries
    Jayme Maniatis or Dana Conti
    Schwartz Communications, Inc.
    Email Contact

    Investor Inquiries
    Lilian Stern
    Stern Investor Relations, Inc.
    Email Contact